Major Customer:	12 Months Ended
Dec. 31, 2011
Major Customer Disclosure [Abstract]
Product,MajorCustomerandConcentrationofCreditRisk [Text Block]	Products, Major Customers and Concentrations of Credit Risks The Company’s primary product groups are infusion therapy, critical care and oncology. Infusion therapy products accounted for $198.9 million, $188.1 million and $152.6 million of revenues in 2011, 2010 and 2009, respectively. Critical care products accounted for $61.4 million, $63.6 million and $51.9 million of revenues in 2011, 2010 and 2009, respectively. Oncology products accounted for $24.4 million, $18.3 million and $14.7 million of revenues in 2011, 2010 and 2009, respectively. The Company sells products worldwide, which are sold on credit terms on an unsecured basis, to medical product manufacturers, independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell the Company’s products to healthcare providers. For the years ended December 31, 2011, 2010 and 2009, the Company had worldwide sales to one manufacturer, Hospira, of 42%, 44% and 54%, respectively, of consolidated revenue. As of December 31, 2011, and 2010, the Company had accounts receivable from Hospira of 36% and 46%, respectively, of consolidated accounts receivable. Domestic sales, which include sales in the United States and Canada, accounted for 76%, 77% and 79% of total revenue in 2011, 2010 and 2009, respectively. International sales, which are determined by the destination of the product shipment, accounted for 24%, 23% and 21% of total revenue in 2011, 2010 and 2009, respectively. As of December 31, 2011, approximately $116.1 million of the Company’s long-lived assets were located in the United States. As of December 31, 2011, approximately $66.8 million of the Company’s long-lived assets, principally property and equipment, were located outside the United States: approximately $46.4 million in Mexico, $15.2 million in Slovakia, $5.0 million in Italy and $0.2 million in Germany. As of December 31, 2010, approximately $104.7 million of the Company’s long-lived assets were located in the United States. As of December 31, 2010, approximately $64.9 million of the Company’s long-lived assets, principally property and equipment, were located outside the United States: approximately $44.6 million in Mexico, $14.7 million in Slovakia, $5.4 million in Italy and $0.2 million in Germany.

Products, Major Customers and Concentrations of Credit Risks

The Company’s primary product groups are infusion therapy, critical care and oncology. Infusion therapy products accounted for $198.9 million, $188.1 million and $152.6 million of revenues in 2011, 2010 and 2009, respectively. Critical care products accounted for $61.4 million, $63.6 million and $51.9 million of revenues in 2011, 2010 and 2009, respectively. Oncology products accounted for $24.4 million, $18.3 million and $14.7 million of revenues in 2011, 2010 and 2009, respectively.

The Company sells products worldwide, which are sold on credit terms on an unsecured basis, to medical product manufacturers, independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell the Company’s products to healthcare providers. For the years ended December 31, 2011, 2010 and 2009, the Company had worldwide sales to one manufacturer, Hospira, of 42%, 44% and 54%, respectively, of consolidated revenue. As of December 31, 2011, and 2010, the Company had accounts receivable from Hospira of 36% and 46%, respectively, of consolidated accounts receivable.

Domestic sales, which include sales in the United States and Canada, accounted for 76%, 77% and 79% of total revenue in 2011, 2010 and 2009, respectively. International sales, which are determined by the destination of the product shipment, accounted for 24%, 23% and 21% of total revenue in 2011, 2010 and 2009, respectively.

As of December 31, 2011, approximately $116.1 million of the Company’s long-lived assets were located in the United States. As of December 31, 2011, approximately $66.8 million of the Company’s long-lived assets, principally property and equipment, were located outside the United States: approximately $46.4 million in Mexico, $15.2 million in Slovakia, $5.0 million in Italy and $0.2 million in Germany. As of December 31, 2010, approximately $104.7 million of the Company’s long-lived assets were located in the United States. As of December 31, 2010, approximately $64.9 million of the Company’s long-lived assets, principally property and equipment, were located outside the United States: approximately $44.6 million in Mexico, $14.7 million in Slovakia, $5.4 million in Italy and $0.2 million in Germany.